AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18815572 — intervention group
Group type: COMPARATOR
Intervention: 600‐m jog
Number of subjects: 68
Study 18815572 — intervention group
Group type: COMPARATOR
Intervention: 600‐m jog followed by a dynamic stretching routine
Number of subjects: 68
Study 18815572 — intervention group
Group type: COMPARATOR
Intervention: 600‐m jog followed by a proprioceptive neuromuscular facilitation (PNF) routine
Number of subjects: 68
Study 16552831 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture stimulation (MAS) at LI 4 point in the right thenar muscle for 2 minutes
Number of subjects: 12
Study 16552831 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 minutes of rest instead of MAS)
Number of subjects: 12
Study 14696632 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 44
Study 14696632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 11033132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/mL for 2 minutes) with releasable sutures (Group 1)
Number of subjects: 36
Study 11033132 — intervention group
Group type: COMPARATOR
Intervention: Permanent sutures (Group 2)
Number of subjects: 36
Study 9388397 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level intervention involving popular homosexual men advocating behaviour change to peers.
Number of subjects: 0
Study 9388397 — intervention group
Group type: COMPARATOR
Intervention: Control cities received HIV educational materials in bars.
Number of subjects: 0
Study 7713197 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI containing salmeterol xinafoate (MDI-S)
Number of subjects: 11850
Study 7713197 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI containing lecithin NF (MDI-L)
Number of subjects: 11850
Study 7713197 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI containing oleic acid (MDI-OA)
Number of subjects: 11850
Study 7713197 — intervention group
Group type: COMPARATOR
Intervention: MDI-S
Number of subjects: 11850
Study 3453431 — intervention group
Group type: COMPARATOR
Intervention: Nicergoline (30 mg twice a day) for 6 months (double-blind for PICD patients)
Number of subjects: 11
Study 3453431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline (30 mg twice a day) for at least 6 months (open design for PAD patients)
Number of subjects: 11
Study 29154884 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP + GNG (cue exposure with Go/No Go training)
Number of subjects: 71
Study 29154884 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP + shamGNG (cue exposure with sham training)
Number of subjects: 71
Study 29154884 — intervention group
Group type: COMPARATOR
Intervention: CON + shamGNG (control procedure with sham training)
Number of subjects: 71
Study 29154884 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 71
Study 27522220 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 0
Study 27522220 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 0
Study 24825805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine injection administered 30 minutes before the biopsy
Number of subjects: 186
Study 24825805 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block (PNB) by injection 10 minutes prior to the prostate biopsy
Number of subjects: 186
Study 24825805 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 62)
Number of subjects: 186
Study 24825805 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 186
Study 23554497 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater effort exerted during anticipation of winning money
Number of subjects: 0
Study 23554497 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort exerted
Number of subjects: 0
Study 23554497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation of effort
Number of subjects: 0
Study 19875270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice followed by physical practice
Number of subjects: 40
Study 19875270 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 40
Study 19875270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 40
Study 19875270 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice followed by mental practice
Number of subjects: 40
Study 19875270 — intervention group
Group type: COMPARATOR
Intervention: No practice
Number of subjects: 40
Study 18681815 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg (8 weeks)
Number of subjects: 370
Study 18681815 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 300/25 mg (8 weeks)
Number of subjects: 370
Study 18681815 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ (overall treatment)
Number of subjects: 370
Study 16899803 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL) program; 1000 kcal/d energy deficit diet with exercise 3 d/wk; 10% weight loss goal
Number of subjects: 87
Study 16899803 — intervention group
Group type: COMPARATOR
Intervention: Weight stable (WS) program; attended health information sessions
Number of subjects: 87
Study 14514935 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management advice from the pharmacist with weekly telephone follow up for 3 months
Number of subjects: 24
Study 14514935 — intervention group
Group type: COMPARATOR
Intervention: No input from the pharmacist (Control)
Number of subjects: 24
Study 10608914 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU or more per day)
Number of subjects: 0
Study 9008978 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-dry environment (HD)
Number of subjects: 8
Study 9008978 — intervention group
Group type: COMPARATOR
Intervention: Hot-wet environment (HW)
Number of subjects: 8
Study 1377830 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART
Number of subjects: 41
Study 1377830 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 41
Study 6536506 — intervention group
Group type: COMPARATOR
Intervention: Postoperative continuous epidural morphine (group C)
Number of subjects: 150
Study 6536506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenoxybenzamine 10 mg (group D)
Number of subjects: 150
Study 6536506 — intervention group
Group type: COMPARATOR
Intervention: Postoperative mild analgesics (group B)
Number of subjects: 150
Study 30641036 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI only group
Number of subjects: 0
Study 30641036 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects with mTBI
Number of subjects: 0
Study 30641036 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial prefrontal cortex connectivity
Number of subjects: 0
Study 30641036 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cingulate cortex connectivity
Number of subjects: 0
Study 30272094 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention (MI)
Number of subjects: 100
Study 30272094 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 Polyunsaturated Fatty Acids supplementation
Number of subjects: 100
Study 30272094 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MI and Omega-3 supplementation
Number of subjects: 100
Study 30272094 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 27974006 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapeutic magnetic resonance (TMR) for 4 weeks
Number of subjects: 0
Study 27974006 — intervention group
Group type: COMPARATOR
Intervention: Sham application of TMR for 4 weeks
Number of subjects: 0
Study 27974006 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapeutic magnetic resonance (TMR) for 4 weeks (restricted to non-ischaemic patients, ABPI >0.8)
Number of subjects: 0
Study 23627924 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre bean-rich diet
Number of subjects: 173
Study 23627924 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet
Number of subjects: 173
Study 22373062 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor feedback (10 to 12 min, maximum of three times)
Number of subjects: 98
Study 22373062 — intervention group
Group type: COMPARATOR
Intervention: No instructor feedback (control group)
Number of subjects: 98
Study 21097484 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDEX II meter for measuring and recording magnetic fields
Number of subjects: 2148
Study 17974883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized bone chips with platelet gel (Group A)
Number of subjects: 33
Study 17974883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized bone chips with platelet gel and bone marrow stromal cells (Group B)
Number of subjects: 33
Study 17974883 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized bone chips without gel (Group C)
Number of subjects: 33
Study 15870129 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg r-hCG
Number of subjects: 60
Study 15870129 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg r-hCG
Number of subjects: 60
Study 12581547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin QD 500 mg once daily for 3 days
Number of subjects: 891
Study 12581547 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin BID 250 mg twice daily for 3 days
Number of subjects: 891
Study 10208475 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 10208475 — intervention group
Group type: COMPARATOR
Intervention: Chlamydia pneumoniae infection
Number of subjects: 0
Study 8665884 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mL
Number of subjects: 120
Study 8665884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 5 mL plus Thiomucase 10 U mL‐1
Number of subjects: 120
Study 8665884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 9 mL
Number of subjects: 120
Study 8665884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 9 mL plus Thiomucase 10 U mL‐1
Number of subjects: 120
Study 8665884 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 2127828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate-based dialysis fluid
Number of subjects: 16
Study 2127828 — intervention group
Group type: COMPARATOR
Intervention: Acetate-based dialysis fluid
Number of subjects: 16
Study 897173 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone preparation
Number of subjects: 58
Study 897173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simethicone preparation)
Number of subjects: 58
Study 31917900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 64
Study 30506144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (starting dose ≤ 0.20 mg/kg)
Number of subjects: 43
Study 30506144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 30506144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 43
Study 28456603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg kg−1) IV over 1 minute
Number of subjects: 41
Study 28456603 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 41
Study 25056999 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based intervention combined with conventional training (30 minutes each)
Number of subjects: 20
Study 25056999 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (1 hour)
Number of subjects: 20
Study 23792072 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine subjects during headache attack phases (ictal)
Number of subjects: 31
Study 23792072 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine subjects during headache‐free phases (interictal)
Number of subjects: 31
Study 23792072 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 31
Study 21315207 — intervention group
Group type: EXPERIMENTAL
Intervention: RB006 (pegnivacogin)
Number of subjects: 0
Study 21315207 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg RB006
Number of subjects: 0
Study 21315207 — intervention group
Group type: EXPERIMENTAL
Intervention: RB006
Number of subjects: 0
Study 21315207 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin or low molecular heparin
Number of subjects: 0
Study 19473505 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex workers (FSW)
Number of subjects: 506
Study 19473505 — intervention group
Group type: COMPARATOR
Intervention: Non-sex workers (non-SW)
Number of subjects: 506
Study 16875447 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (8 J/cm2 each day for five consecutive days using super luminous diodes with wavelengths of 880 and visible diodes of 660 nm)
Number of subjects: 27
Study 16875447 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 27
Study 16875447 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (identical treatment from a dummy cluster)
Number of subjects: 27
Study 16875447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study 12894309 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic abdominoperineal resection
Number of subjects: 28
Study 12894309 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 28
Study 10841242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency (RF) catheter ablation with internal saline irrigation
Number of subjects: 146
Study 9410047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg/day over 5 days)
Number of subjects: 174
Study 9410047 — intervention group
Group type: COMPARATOR
Intervention: Diacetylmidecamycin (600 mg, twice daily over 7 days)
Number of subjects: 174
Study 1390171 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/g) applied twice daily
Number of subjects: 478
Study 1390171 — intervention group
Group type: COMPARATOR
Intervention: Dithrocream (dithranol) applied for 30 min each day
Number of subjects: 478
Study 4047707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 400 mg
Number of subjects: 120
Study 4047707 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine, 300 mg plus 30 mg
Number of subjects: 120
Study 4047707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30799926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive risk factor intervention during the first year post-stroke
Number of subjects: 195
Study 30799926 — intervention group
Group type: COMPARATOR
Intervention: Usual care during the first year post-stroke
Number of subjects: 195
Study 30799926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ITT and CC populations)
Number of subjects: 195
Study 30799926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards regression analysis
Number of subjects: 195
Study 28960384 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-GSH + Noom
Number of subjects: 66
Study 28960384 — intervention group
Group type: COMPARATOR
Intervention: CBT-GSH
Number of subjects: 66
Study 27423320 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based participatory research (CBPR) developed, multi‐level smoking cessation intervention with 1:1 community health worker contact, behavioral peer group sessions, and nicotine replacement for 24 weeks
Number of subjects: 409
Study 27423320 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based participatory research (CBPR) developed, multi‐level smoking cessation intervention
Number of subjects: 409
Study 27423320 — intervention group
Group type: COMPARATOR
Intervention: Control group received written cessation materials at weeks 1, 6, 12, 18
Number of subjects: 409
Study 27423320 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 409
Study 27423320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants who kept coach visits, attended group sessions, and used patches
Number of subjects: 409
Study 27423320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 409
Study 24685561 — intervention group
Group type: EXPERIMENTAL
Intervention: $3 predictable amount
Number of subjects: 15
Study 24685561 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic amounts (50% chance of $6; 25% chance of $12; 12.5% chance of $24)
Number of subjects: 15
Study 24685561 — intervention group
Group type: COMPARATOR
Intervention: $1 predictable amount
Number of subjects: 15
Study 24685561 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg cocaine units
Number of subjects: 15
Study 24685561 — intervention group
Group type: COMPARATOR
Intervention: 0-mg cocaine units
Number of subjects: 15
Study 22066530 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (20 mg of rabeprazole, 1 g of amoxicillin, and 500 mg of clarithromycin, twice daily for 7 days)
Number of subjects: 348
Study 22066530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (5-day dual therapy: 20 mg of rabeprazole and 1 g of amoxicillin, twice daily, followed by 5-day triple therapy: 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily)
Number of subjects: 348
Study 20440474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 267
Study 20440474 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape-obturator (TVT-O)
Number of subjects: 267
Study 20440474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (TVT and TVT-O)
Number of subjects: 267
Study 17535291 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like growth factor I (IGF-I)
Number of subjects: 747
Study 17535291 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 747
Study 15664680 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ME (climbed up and down stairs)
Number of subjects: 32
Study 15664680 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ES (practised electrostimulation)
Number of subjects: 32
Study 15664680 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ME + ES (undertook both activities)
Number of subjects: 32
Study 12127431 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg lamivudine daily for 4 weeks
Number of subjects: 21
Study 12127431 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lamivudine daily for 4 weeks
Number of subjects: 21
Study 12127431 — intervention group
Group type: COMPARATOR
Intervention: Previous lamivudine treatment
Number of subjects: 21
Study 12127431 — intervention group
Group type: COMPARATOR
Intervention: Naive to lamivudine treatment
Number of subjects: 21
Study 10198369 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IGF-I, 50 microgram/kg/day
Number of subjects: 15
Study 10198369 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 15
Study 7786592 — intervention group
Group type: EXPERIMENTAL
Intervention: platinum-based combination chemotherapy with or without doxorubicin (DX)
Number of subjects: 129
Study 1706741 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 5 million units subcutaneously 3 times a week for 24 weeks
Number of subjects: 15
Study 1706741 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 15
Study 395854 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (mean dose 130 mg)
Number of subjects: 44
Study 395854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (mean dose 183.3 mg)
Number of subjects: 44
Study 395854 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 44
Study 395854 — intervention group
Group type: COMPARATOR
Intervention: Pethidine reversed by naloxone (200 micrograms intramuscularly)
Number of subjects: 44
Study 395854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 44
Study 30248035 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization workouts
Number of subjects: 120
Study 30248035 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy
Number of subjects: 120
Study 28733999 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl propionate and climbazole (RPC)
Number of subjects: 45
Study 28733999 — intervention group
Group type: COMPARATOR
Intervention: 0.1% retinol
Number of subjects: 45
Study 26001561 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate 100 mg
Number of subjects: 422
Study 26001561 — intervention group
Group type: COMPARATOR
Intervention: Monthly intravenous ibandronate 1 mg
Number of subjects: 422
Study 24113041 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d) plus Policosanol (20 mg/d)
Number of subjects: 120
Study 24113041 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg/d) plus Placebo (20 mg/d)
Number of subjects: 120
Study 21840329 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA‐S 100mg/day for 3 months
Number of subjects: 61
Study 21840329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 19699113 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% EDTA
Number of subjects: 40
Study 19699113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% EDTA
Number of subjects: 40
Study 19699113 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EDTA
Number of subjects: 40
Study 19699113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% EDTA
Number of subjects: 40
Study 19699113 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal vs Apical thirds
Number of subjects: 40
Study 19699113 — intervention group
Group type: COMPARATOR
Intervention: Different concentrations of EDTA
Number of subjects: 40
Study 17873142 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicorandil (15 mg/d) - Group A
Number of subjects: 40
Study 17873142 — intervention group
Group type: COMPARATOR
Intervention: Placebo - Group B
Number of subjects: 40
Study 16287769 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized alerts and collaboration among healthcare professionals
Number of subjects: 400000
Study 16287769 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400000
Study 16287769 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized alerts for amiodarone
Number of subjects: 400000